未登录.png)
分享.png)
收藏Post-recurrence survival in patients with stage III gastric cancer who received adjuvant chemotherapy; post-hoc analysis of the JACCRO GC-07 studyIII期胃癌患者接受辅助化疗后的复发后生存情况；JACCRO GC-07研究的事后分析
Ishida, Hiroo; Sunakawa, Yu; Kodera, Yasuhiro; Yoshida, Kazuhiro; Kochi, Mitsugu; Kakeji, Yoshihiro; Sano, Takeshi; Takeuchi, Masahiro; Ichikawa, Wataru; Fujii, Masashi 分享 收藏 Modified FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type metastatic colorectal cancer: a randomized phase II DEEPER trialShiozawa, Manabu; Sunakawa, Yu; Watanabe, Takanori; Ota, Hirofumi; Yasui, Hisateru; Yabuno, Taichi; Tei, Mitsuyoshi; Kochi, Mitsugu; Manaka, Dai; Ohori, Hisatsugu; Yamaguchi, Tatsuro; Sagawa, Tamotsu; Kotaka, Masahito; Kubota, Yutaro; Sekikawa, Takashi; Nakamura, Masato; Takeuchi, Masahiro; Ichikawa, Wataru; Fujii, Masashi; Tsuji, Akihito 分享 收藏 Number of Sites of Involvement Predicts Central Nervous System Relapse in Patients with Localized Extranodal Natural Killer/T-Cell Lymphoma累及部位数量可预测局限性结外自然杀伤/T细胞淋巴瘤患者的中枢神经系统复发。Nato, Yuma; Miyazaki, Kana; Fujimoto, Ayumi; Taguchi, Senzo; Asano, Naoko; Amaki, Jun; Munakata, Wataru; Shirouchi, Yuko; Kubota, Nobuko; Maeda, Takeshi; Takizawa, Jun; Yakushijin, Kimikazu; Sakai, Rika; Nakazawa, Hideyuki; Takeuchi, Masahiro; Fukuhara, Noriko; Miyazawa, Yuri; Tokiya, Ryoji; Murayama, Tohru; Tawara, Isao; Ejima, Yasuo; Suzuki, Ritsuro; Yamaguchi, Motoko 分享 收藏 Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter StudyShoji, Jun; Goggins, William C.; Wellen, Jason R.; Cunningham, Patrick N.; Johnston, Olwyn; Chang, Shirley S.; Solez, Kim; Santos, Vicki; Larson, Tami J.; Takeuchi, Masahiro; Wang, Xuegong 分享 收藏 Addition of docetaxel to S-1 results in significantly superior 5-year survival outcomes in Stage III gastric cancer: a final report of the JACCRO GC-07 study (vol 26, 1063, 2023)Kodera, Yasuhiro; Yoshida, Kazuhiro; Kochi, Mitsugu; Sano, Takeshi; Ichikawa, Wataru; Kakeji, Yoshihiro; Sunakawa, Yu; Takeuchi, Masahiro; Fujii, Masashi 分享 收藏 分享 收藏 Survival analysis of m-FOLFOXIRI plus cetuximab vs. bevacizumab in RAS wild-type mCRC: The DEEPER trial (JACCRO CC-13)Tsuji, Akihito; Endo, Izuru; Kobayashi, Kenji; Miyamoto, Yuji; Kusumoto, Tetsuya; Yuasa, Yasuhiro; Miwa, Keisuke; Kochi, Mitsugu; Sagawa, Tamotsu; Kotaka, Masahito; Kubota, Yutaro; Sunakawa, Yu; Sekikawa, Takashi; Nakamura, Masato; Takeuchi, Masahiro; Ichikawa, Wataru; Fujii, Masashi 分享 收藏 Modified (m)-FOLFOXIRI plus cetuximab treatment and predictive clinical factors for RAS/BRAF wild-type and left-sided metastatic colorectal cancer (mCRC): The DEEPER trial (JACCRO CC-13)Sunakawa, Y.; Shiozawa, M.; Watanabe, T.; Ota, H.; Yasui, H.; Kochi, M.; Manaka, D.; Ohori, H.; Yamaguchi, T.; Matsuura, M.; Shinohara, Y.; Miyake, T.; Sagawa, T.; Tanaka, C.; Okamura, S.; Takeuchi, M.; Ichikawa, W.; Fujii, M.; Tsuji, A. 分享 收藏 The efficacy of anti-EGFR therapy for RAS mutant metastatic colorectal cancer (mCRC) patients with RAS mutation negative in circulating-tumor DNA (ctDNA) after 1st-or 2nd-line chemotherapyIzawa, N.; Kudo, T.; Yuki, S.; Nakamura, M.; Manaka, D.; Kumekawa, Y.; Mine, T.; Okuno, T.; Oda, H.; Sagawa, T.; Kawai, T.; Shingai, T.; Kotaka, M.; Kobayashi, K.; Kagawa, Y.; Satake, H.; Takeuchi, M.; Ichikawa, W.; Fujii, M.; Sunakawa, Y. 分享 收藏 Ramucirumab plus FOLFIRI as second-line treatment for patients with RAS wild-type metastatic colorectal cancer previously treated with anti-EGFR antibody: JACCRO CC-16Yasui, H.; Okita, Y.; Nakamura, M.; Sagawa, T.; Watanabe, T.; Kataoka, K.; Manaka, D.; Shiraishi, K.; Akazawa, N.; Okuno, T.; Shimura, T.; Shiozawa, M.; Sunakawa, Y.; Ota, H.; Kotaka, M.; Okuyama, H.; Takeuchi, M.; Ichikawa, W.; Fujii, M.; Tsuji, A. 分享 收藏 分享 收藏 Phase II trial of biweekly administration with eribulin after three cycles of induction therapy in hormone receptor-positive, HER2-negative metastatic breast cancer (JACCRO BC-03)Kobayashi, Kokoro; Masuda, Norikazu; Mizuno, Toshiro; Miura, Kayo; Tokuda, Yutaka; Yoshinami, Tetsuhiro; Kawaguchi, Hidetoshi; Ohtani, Shoichiro; Saeki, Toshiaki; Toi, Masakazu; Takeuchi, Masahiro; Ito, Yoshinori 分享 收藏 Modified (m)-FOLFOXIRI plus cetuximab versus m-FOLFOXIRI plus bevacizumab as initial treatment for RAS and BRAF wild-type metastatic colorectal cancer: Updated survival analysis of the DEEPER trial by JACCROSunakawa, Y.; Shiozawa, M.; Watanabe, T.; Ota, H.; Yasui, H.; Kochi, M.; Manaka, D.; Ohori, H.; Yamaguchi, T.; Kyogoku, T.; Sagawa, T.; Kubota, Y.; Masuishi, T.; Kotaka, M.; Sekikawa, T.; Shimada, K.; Nakamura, M.; Takeuchi, M.; Ichikawa, W.; Fujii, M.; Tsuji, A. 分享 收藏 Double-hit follicular lymphoma diagnosed due to central nervous system symptomsKawajiri-Manako, Chika; Mishina, Tatsuzo; Tsujimura, Hideki; Maruyama, Satoshi; Sato, Akiyasu; Sugawara, Takeaki; Kumagai, Kyoya; Nakamura, Rikiya; Itami, Makiko; Takeuchi, Masahiro 分享 收藏 分享 收藏 分享 收藏 Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to 1st-line treatment with anti-EGFR antibody: JACCRO CC-16Sagawa, Tamotsu; Tsuji, Akihito; Satake, Hironaga; Nakamura, Masato; Sunakawa, Yu; Korehisa, Shotaro; Matsuura, Masato; Yuasa, Yasuhiro; Mine, Takashi; Nagano, Hiroaki; Shigeyasu, Kunitoshi; Kinjo, Tatsuya; Kotaka, Masahito; Okuyama, Hiroyuki; Kubota, Yutaro; Kochi, Mitsugu; Masuishi, Toshiki; Takeuchi, Masahiro; Ichikawa, Wataru; Fujii, Masashi 分享 收藏 分享 收藏 FOLFOXIRI plus cetuximab versus bevacizumab in RAS wild-type mCRC: the subgroup-analysis of DEEPER trial (JACCRO CC-13)Yabuno, Taichi; Tsuji, Akihito; Tokunaga, Takuya; Yuki, Satoshi; Kudo, Toshihiro; Mashita, Naoki; Ando, Koji; Takeuchi, Nobumichi; Kashiwada, Tomomi; Kataoka, Masato; Kochi, Mitsugu; Sagawa, Tamotsu; Kotaka, Masahito; Kubota, Yutaro; Sunakawa, Yu; Sekikawa, Takashi; Nakamura, Masato; Takeuchi, Masahiro; Ichikawa, Wataru; Fujii, Masashi 分享 收藏 
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
.png){kind=icon}
